CompletedPhase 3

Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)

United States, Bulgaria240 participantsStarted 2018-07-26

Plain-language summary

The objectives of this study are to assess the efficacy, safety, and tolerability of PLX-PAD intramuscular administration for the treatment of muscle injury following arthroplasty for HF.

Who can participate

Age range0 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female subjects
✓. Subjects up to 90 years of age, inclusive, at the time of Screening
✓. Subjects suffering low energy trauma with intracapsular neck of femur fracture.
✓. Planned to be treated with total hip arthroplasty (THA) or hemi-arthroplasty (HA) within 48 hours of hospital admission and 72 hours post fracture.
✓. Subjects able to walk 10 feet/3 meters before the fracture.
✓. Signed an informed consent.

What they're measuring

Short Physical Performance Battery (SPPB) score

Timeframe: Week 26.

Trial details

NCT IDNCT03451916

SponsorPluristem Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-04-29

View on ClinicalTrials.gov More Hip Fracture trials